膀胱癌病理分级与PGAP2基因表达的相关性及分子生物学关系的研究

刘玉錾; 宋颖刚; 高昆; 高双友

doi:10.13201/j.issn.1001-1420.2021.05.009

膀胱癌病理分级与PGAP2基因表达的相关性及分子生物学关系的研究

- 1. 开滦总医院林西医院泌尿外科(河北唐山, 063100);
- 2. 开滦总医院泌尿外科

详细信息

通讯作者: 高双友,E-mail:gaoshuangyou@163.com

中图分类号: R737.14

收稿日期: 2020-07-17

Study on the relationship between PGAP2 gene expression and pathological grade of bladder cancer and molecular biology

- 1. Department of Urology, Linxi Hospital of Kailuan General Hospital, Tangshan, Hebei, 063100, China;
- 2. Department of Urology, Kailuan General Hospital

More Information

Corresponding author: GAO Shuangyou, E-mail: gaoshuangyou@163.com

Received Date: 17 July 2020

摘要

摘要: 目的:检测不同病理分级膀胱癌患者组织PGAP2表达水平,并探讨其表达水平与膀胱癌病理分级及分子生物学关系。方法:选取2011年8月—2015年4月于开滦总医院林西医院住院的78例膀胱癌患者肿瘤组织作为肿瘤组,膀胱癌患者均为尿路上皮癌,组织学分级按照WHO分级标准:Ⅰ级24例、Ⅱ级29例、Ⅲ级25例;根据膀胱癌患者肿瘤组织PGAP2 mRNA水平平均值,将患者分为PGAP2高表达组(n=39)和PGAP2低表达组(n=39);根据患者出院后5年内是否出现复发或因膀胱癌死亡,将患者分为预后良好46例和预后不良32例。选取膀胱癌患者相应癌旁正常组织作为正常组。采用实时荧光定量PCR(qRT-PCR)法检测膀胱癌肿瘤组织及癌旁正常组织PGAP2 mRNA水平;Ualcan数据库检索验证PGAP2在正常膀胱组织及膀胱癌肿瘤组织中的表达;分析肿瘤组织PGAP2 mRNA水平与膀胱癌患者病理分级等临床病理特征的关系;多因素Cox回归分析影响膀胱癌预后的因素。结果:肿瘤组PGAP2 mRNA水平高于正常组,差异有统计学意义(P<0.05),与Ualcan数据库结果一致;PGAP2高表达组肿瘤多发、组织浸润深度为肌层浸润性膀胱癌、预后不良的患者比例均高于PGAP2低表达组,差异有统计学意义(P<0.05);肿瘤组织PGAP2表达水平与膀胱癌病理组织学分级有关,差异有统计学意义(P<0.05);病理分级、PGAP2是影响膀胱癌预后的独立危险因素(P<0.05)。结论:膀胱癌患者肿瘤组织PGAP2表达水平与病理分级等临床病理特征密切相关,且是影响膀胱癌预后的独立危险因素,可对膀胱癌的病情评价及治疗提供一定理论依据。
- 膀胱癌 /
- 病理分级 /
- 肿瘤组织 /
- PGAP2基因
Abstract: Objective: To detect the expression level of PGAP2 in different pathological grades of bladder cancer, and to explore the relationship between the expression level and pathological grades and molecular biology of bladder cancer.Methods: From August 2011 to April 2015, bladder cancer tissues from 78 patients in Linxi Hospital of Kailuan General Hospital were selected as tumor group, and all bladder cancer patients were urothelial cancer. According to WHO classification standard, the histological classification was: 24 cases of grade Ⅰ, 29 cases of grade Ⅱ, 25 cases of grade Ⅲ. According to the average level of PGAP2 mRNA in bladder cancer, the patients were divided into two groups: PGAP2 high expression group(n=39)and PGAP2 low expression group(n=39). According to the recurrence or death of bladder cancer within 5 years after discharge, the patients were divided into 46 with good prognosis and 32 with poor prognosis. The normal tissues adjacent to the bladder cancer were selected as the normal group. The level of PGAP2 mRNA in tumor tissue of bladder cancer and normal tissues adjacent to the bladder cancer were detected by real-time fluorescence quantitative PCR(qRT-PCR), and the expression of PGAP2 in normal bladder tissue and bladder cancer tissue were verified by the search of Ualcan database. The relationship between PGAP2 mRNA level in tumor tissue and clinicopathological characteristics of bladder cancer patients was analyzed, and multivariate Cox regression was used to analyze the prognostic factors of bladder cancer.Results: The level of PGAP2 mRNA in tumor group was higher than that in normal group. The difference was statistically significant(P<0.05), which was consistent with the result of Ualcan database. The proportions of patients with multiple tumors, infiltration depth of muscle layer invasive bladder cancer and poor prognosis in PGAP2 high expression group were higher than those in PGAP2 low expression group, and the difference was statistically significant(P<0.05). The expression level of PGAP2 was related to the histopathological grade of bladder cancer, and the difference was statistically significant(P<0.05). Pathological grade and PGAP2 were independent risk factors for prognosis of bladder cancer(P<0.05).Conclusion: The expression level of PGAP2 in bladder cancer tissues is closely related to the clinicopathological characteristics such as pathological grade, and is an independent risk factor for the prognosis of bladder cancer. It can provide a theoretical basis for the evaluation and treatment of bladder cancer.
- bladder cancer /
- pathological grade /
- tumor tissue /
- PGAP2 gene

HTML全文

参考文献(21)

[1]	王庆伟,张涛,文建国,等.上尿路尿路上皮癌预后多因素分析及术后再发膀胱癌危险因素分析[J].临床泌尿外科杂志,2018,33(5):385-389.
[2]	Longdon E,Mistry H,Pratt O,et al.Variables associated with survival in patients with invasive bladder cancer with and without surgery[J].Anaesthesia,2020,75(7):887-895.
[3]	苏宏伟,刘军超,李婷,等.T淋巴瘤侵袭转移诱导因子1在膀胱癌组织中的表达及其与膀胱癌复发的关系[J].广西医学,2019,41(11):1376-1380.
[4]	韩耕宇,李华福,许宸,等.不同侵袭性膀胱癌患者预后与基因差异表达研究[J].转化医学电子杂志,2018,5(11):14-18.
[5]	Abbosh PH,Plimack ER.Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer[J].Bladder Cancer,2018,4(1):9-18.
[6]	陈奇,武惠韬,孙金秀,等.胃癌转移的分子特征分析及预后评估[J].解放军医学院学报,2019,40(8):745-749.
[7]	黄文斌,程亮.2016版WHO膀胱肿瘤新分类解读[J].中华病理学杂志,2016,45(7):441-445.
[8]	何天基,葛波.肌层浸润性膀胱癌新辅助治疗现状及展望[J].临床泌尿外科杂志,2020,35(2):158-161.
[9]	Moschini M,Zaffuto E,Karakiewicz P,et al.The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer[J].World J Urol,2019,37(6):1127-1135.
[10]	Yao Z,Jiang Y,Zhu X,et al.Risk factors and oncological outcomes of urethral recurrence in male patients with muscle invasive bladder cancer after radical cystectomy combined with urinary diversion:a propensity score-matched case control study[J].Int J Clin Oncol,2020,25(7):1377-1384.
[11]	Saleh AA,Gohar SF,Hemida AS,et al.Evaluation of ASPM and TEF Gene Expressions as Potential Biomarkers for Bladder Cancer[J].Biochem Genet,2020,58(3):490-507.
[12]	刘忠清,任明华,贾光,等.代谢酶的基因多态性与膀胱癌易感性关系的研究与进展[J].国际遗传学杂志,2018,41(1):50-55.
[13]	Guo X,Liu M,Hou H,et al.Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer[J].Int J Clin Oncol,2019,24(8):957-965.
[14]	姜帅,项卓仪.2019年膀胱癌诊治进展[J].上海医学,2020,43(6):336-340.
[15]	吴腾辉,彭镜.PIG/PGAP基因及其相关表型研究进展[J].中华实用儿科临床杂志,2019,34(9):714-717.
[16]	韩倩倩,周琴,张兰兰,等.uPAR在肿瘤诊断与治疗中的研究进展[J].生物学杂志,2019,36(5):85-88.
[17]	Nieder C,Haukland E,Pawinski A,et al.Seven-month prostate-specific antigen(PSA)is prognostic in patients with prostate cancer initially diagnosed with distant metastases[J].Med Oncol,2018,35(4):46-56.
[18]	王明丽,徐笑红,单绿虎,等.癌胚抗原、铁蛋白等肿瘤标志物对肺癌的诊断价值[J].中国卫生检验杂志,2019,29(1):1-3.
[19]	Ejaz SA,Saeed A,Shah S,et al.Distinctive inhibition of alkaline phosphatase isozymes by thiazol-2-ylidene-benzamide derivatives:Functional insights into their anticancer role[J].J Cell Biochem,2018,119(8):6501-6513.
[20]	Fogeron ML,Müller H,Schade S,et al.LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells[J].Nat Commun,2013,4:1531.
[21]	Huttlin EL,Bruckner RJ,Paulo JA,et al.Architecture of the human interactome defines protein communities and disease networks[J].Nature,2017,545(7655):505-509.